Ann: OncoSil Medical CE Mark Update, page-95

'
In the medical innovation space, look for continued new cancer treatments around targeted oncology products. Immuno-oncology drugs and bracytherapies (advanced radiation tumour treatments) will continue to grow at record pace. Oncology is now being seen as a disease space that can be managed by multiple treatments in the same way as we see today in the HIV / AIDS infectious disease space.
With treatments for the body coming good, the industry is turning to treating diseases of the brain and we should also see a boom in brain medicine, thanks to scientific advances such as genetic sequencing and new DNA editing techniques, along with a better scientific understanding of the overwhelming complexity of illnesses that afflict the brain and how to treat them. A record amount of $US3.3 billion was invested last year alone in the space of brain-destroying illnesses. Look no further than treatments focused on Alzheimer's disease, which directly cost the US healthcare system $US250 billion in 2015. I'm involved in both spaces, as chairman of ASX-listed Actinogen Medical and a board member of Oncosil Medical.

So while many are cautious about the outlook for the coming year, I'm partying like it's 1998.
Martin Rogers is a start-up investor and company director.

Read more: http://www.copyright link/opinion/in-innovation-and-biotech-lets-party-like-its-1998-20160103-glyff4#ixzz3wFq8EZGg
Follow us: @FinancialReview on Twitter | financialreview on Facebook'​